Boehringer Ingelheim plans to acquire NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC™ platform … more
Boehringer-Ingelheim also plans to acquire Labor Dr. Merk & Kollegen. The acquisition will enable Boehringer Ingelheim to further expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies including the Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP) platform and cancer vaccines platforms … more
Boehringer Ingelheim and Proxygen have entered into a collaboration and license agreement to enable the identification of molecular glue degraders against various oncogenic targets. The collaboration combines Proxygen’s unique molecular glue degrader discovery platform and its expertise in targeted protein degradation with Boehringer Ingelheim’s long-term strategy to provide first-in-class, breakthrough therapies for cancer patients … more